ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / LPCN / forecast
RKTO (40) KTTA (40) CLRB (32) ASBP (40) ⌘ Pro Terminal →

Lipocine Inc. (LPCN) 12-Month Stock Forecast & Price Target Cone

$1.44 -5.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.42

Lipocine Inc. (LPCN) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $11.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LPCN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LPCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Lipocine Inc. (NASDAQ: LPCN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $1.44 (-5.26% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LPCN ranks #955 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LPCN compare to RKTO and KTTA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LPCN carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RKTO (Rocket One Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.1M) and KTTA (Pasithea Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M). Among the 5-stock peer group, LPCN leads on earnings multiple (N/A) while LPCN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LPCN?
▼

Per LPCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001535955), Lipocine Inc. generated $2.0M in revenue (-82.3% YoY), -$9.6M in net income, and -$9.8M in free cash flow against $17.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.42 (-1.14%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510023
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (3)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-16% Base Target
$13 Bull$1 Base$1 Bear
📬 FREE LPCN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LPCN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (23/100 Composite)
🔍 WHY LPCN SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (30% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$1.62+0% Next Q
Q2 (-2Q)
28
Grade E$1.62-9.9% Next Q
Q3 (-1Q)
26
Grade E$1.46-1.4% Next Q
Current
23
Grade E$1.44-11.1% Hist 90D α
Trajectory: E (31) → E (23)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LPCN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LPCN currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.96) and Max Pain ($1.51) forces dealer call-delta covering toward $12.99.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LPCN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LPCN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 23%NO 77%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your LPCN Position Size: $10,000

Shares at $1.44: 6944.4 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.94
$6,528
$-3,472 (-34.7%)
12M Consensus BaseTarget $1.21
$8,403
$-1,597 (-16.0%)
12M Bull Case BreakoutTarget $12.99
$90,208
+$80,208 (+802.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1269%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LPCN)

  • ✓Walkthrough of LPCN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LPCN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.12%📐 HORIZONTAL RANGE
2026-11-03O $1.52H $1.52L $1.44C $1.44VOL 112.1K
RES: $3.27SUP: $1.25SMA50: $1.96SMA200: $3.82
$5.88$4.67$3.45$2.24$1.02RES $3.27SUP $1.25$1.442026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LPCN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LPCN Butterfly Map → + Track LPCN →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LPCN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LPCN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LPCN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LPCN)

Health Care Rank #955 of 1016 ⚔️ RKTO vs LPCN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LPCN vs. RKTO, KTTA, CLRB, ASBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lipocine Inc. (LPCN) ranks #955 by composite RQD confidence (23/100, grade E) and #878 by equity capitalization ($11.9M). Within this direct 5-issuer industry benchmark cohort, LPCN leads on earnings valuation at N/A trailing P/E, while LPCN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RKTO currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with LPCN at 23/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LPCN ACTIVE
Lipocine Inc.
E 23/100 — — -35.0% -5.26% $11.9M Benchmark Subject
RKTO
Rocket One Inc.
D- 40/100 — — -35.0% -5.60% $12.1M /rkto-vs-lpcn →
KTTA
Pasithea Therapeutics Corp.
D- 40/100 — — -35.0% +0.16% $12.4M /ktta-vs-lpcn →
CLRB
Cellectar Biosciences Inc.
E 32/100 — — -35.0% -1.23% $11.4M /clrb-vs-lpcn →
ASBP
Aspire-Lakewood Holdings Inc.
D- 40/100 — -1.9% -35.0% -4.36% $11.4M /asbp-vs-lpcn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001535955

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lipocine Inc. (LPCN) reported GAAP revenue of $2.0M (-82.3% vs. FY2024 revenue of $11.2M , and +169.3% cumulative change since FY2023) , GAAP net income of -$9.6M, operating cash flow of -$9.8M, and free cash flow of -$9.8M (-644.3% YoY). On the balance sheet, LPCN closed FY2025 with $17.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.0M -$9.6M -$9.8M -$9.8M $17.0M —
FY2024 (FY) 2024-12-31 $11.2M $10.0K -$1.2M -$1.3M $22.5M —
FY2023 (FY) 2023-12-31 -$2.9M -$16.4M -$11.9M -$11.9M — —

3. LPCN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LPCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lipocine Inc. (NASDAQ: LPCN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $1.44 (-5.26% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LPCN ranks #955 in composite RQD confidence.

How does LPCN compare to RKTO and KTTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LPCN carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RKTO (Rocket One Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.1M) and KTTA (Pasithea Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M). Among the 5-stock peer group, LPCN leads on earnings multiple (N/A) while LPCN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LPCN?

Per LPCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001535955), Lipocine Inc. generated $2.0M in revenue (-82.3% YoY), -$9.6M in net income, and -$9.8M in free cash flow against $17.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LPCN trading relative to its 50-day, 200-day, and 52-week technical levels?

LPCN last traded at $1.44 (-5.26% on volume of 112,053 shares), positioning the stock -26.53% below its 50-day simple moving average ($1.96) and -62.30% below its 200-day simple moving average ($3.82). Across its 52-week range of $1.40 to $12.37, LPCN sits at the 0.4% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.26 to $1.62).

Direct Sub-Reports: LPCN RQD Cockpit LPCN 12M Forecast LPCN Earnings & Move LPCN Dividends & DRIP LPCN Insiders & 13F LPCN Whale Options LPCN Profit Sankey LPCN News & Why
ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LPCN — Lipocine Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:51:12Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LPCN scores 23 out of 100 with a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

  • Fundamental Cash Engine: 5 / 20 (ROIC -35%; FCF yield 0%). This is the weakest operating signal: the business is not currently generating a return on invested capital or free cash flow relative to its value. For a prospective investor, this means the stock has no present cash-earnings support, so any upside depends on future developments not yet visible in reported results.
  • Whale 13F Flow: 3 / 20 (Institutional accumulation & options positioning). Institutional positioning is scored very low, indicating limited smart-money conviction. The source provides no holder detail, so the specific drivers of this score cannot be verified.
  • Insider Conviction: 3 / 20 (SEC Form 4 & Congressional PTR cluster flow). Insider and related-party flow is scored low, offering little alignment signal from people with direct knowledge of the company.
  • Macro Regime Fit: 7 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock moves in line with the broad market. The score reflects limited favorable macro positioning rather than a distinct macro thesis.
  • Forensic Balance Sheet: 5 / 20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The Piotroski score of 1 out of 9 signals weak financial-health indicators, while the Altman Z of 2.5 and Debt/Equity of 0.5 are the more moderate readings in the set.

Investor implications: the combined picture is one of weak cash generation, low institutional and insider conviction, and a fragile forensic profile. Valuation tradeoffs are significant, because the market price of $1.52 and market capitalization of $12.5M sit against negative operating and net margins.

Business

Lipocine Inc. (LPCN) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. it is an issuer in this industry with a market capitalization stated as $0.0B. Per the financials, reported revenue was $2.0M in FY 2025 and $11.2M in FY 2024. Details on specific products, customers, and revenue model are —

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six LPCN-related items are listed, each flagged YELLOW with the impact label MARKET WIRE:

  • A Yahoo Finance report headlined "LPCN Stock Is Surging: Here's Why Lipocine Is On Traders' Radar Today."
  • A TradingView report headlined "Here's Why You Should Add LPCN Stock to Your Portfolio Now."
  • A Stocktwits report with the same surge headline as the Yahoo item.
  • A StockInvest.us forecast headlined "Lipocine Stock Price Forecast. Should You Buy LPCN?"
  • A Stock Titan item reporting that Canada approved a testosterone pill for men, with launch planned by year-end.
  • A Timothy Sykes item headlined "LPCN Stock Pops As BLOOM Phase 3 Trial Kicks Off."

Catalysts: the Canadian approval and the BLOOM Phase 3 trial start are the most substantive items. Risk watch: several items are promotional or price-action commentary rather than company disclosures, and the source does not confirm the drivers of the reported price move. Proprietary signals: none are listed in the Butterfly Supply-Chain Graph.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are — The investor should note that the Canadian approval and BLOOM trial, if they materialize as commercial or development milestones, would be the primary channels through which external events could affect the company, but the source does not quantify these links.

Open Questions

  • What are the commercial terms, timing, and revenue potential of the Canadian testosterone product approval, and do they offset the FY 2025 revenue decline?
  • What is the expected timeline, funding, and cost of the BLOOM Phase 3 trial, and how long does current cash of $5.2M sustain operations at the FY 2025 FCF rate of $-9.8M?
  • What drove the FY 2025 revenue drop from $11.2M to $2.0M, and is it recurring?
  • What are the company's debt obligations, given that the source reports debt as N/A for all periods while Debt/Equity is 0.5?
  • Why are EPS, P/E, and EV/EBITDA unavailable, and how do they compare with peers?

LPCN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lipocine Inc. (LPCN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LPCN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LPCN Bull vs. Bear Conversation Board — What's Your Call at $1.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LPCN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LPCN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA Institutional Buy-Side 🐂 BULLISH 🎯 Target: $1.68 (+16.7%)
📌 Pinned Debate

LPCN (E • RQD 23/100) operating leverage in Biotechnology: Pharmaceutical Preparations is mispriced at $1.44

The street is overcomplicating Lipocine Inc. (LPCN). LPCN (E • RQD 23/100) operating leverage in Biotechnology: Pharmaceutical Preparations is mispriced at $1.44. With an RQD score of 23/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.56.

ArenaChamp_24 🐂 BULL

@DeepValue_CFA Agree on the RQD 23/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.44 and keeping dry powder in case we test $1.34.

FA FadeTheHype Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.20 (-16.7%)
Spot @ $1.44

Revenue fell from $11.2M to $2.0M while FCF was $-9.8M and ROIC was -35%, with a Piotroski F-Score of 1 out of 9.

Careful chasing LPCN at $1.44. Revenue fell from $11.2M to $2.0M while FCF was $-9.8M and ROIC was -35%, with a Piotroski F-Score of 1 out of 9.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.20 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%